Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis

Urology

Volumn 67, Issue 6, 2006, Pages 1253-1256

  Berglund, Ryan K ^a   Jones, J Stephen ^a   Ulchaker, James C ^a   Fergany, Amr ^a   Gill, Inderbir ^a   Kaouk, Jihad ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; GONADORELIN AGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; DATA BASE; FEASIBILITY STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE DISEASE;

FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 33744527148     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.12.003     Document Type: Article

References (13)

1. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
2. Kupelian P., Buchsbaum J., Elshaikh M., et al. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 95 (2002) 2302-2307
3. Ward J., Slezak J., Blute M., et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing. 15-year outcome. BJU Int 95 (2005) 751-756
4. Bader P., Burkhard F., Markwalder R., et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. is there a chance of cure?. J Urol 169 (2003) 849-854
5. Thompson I., Tangen C., Basler J., et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168 (2002) 1008-1012
6. Coen J., Zietman A., Thakral H., et al. Radical radiation for localized prostate cancer. local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199-3205
7. Johansson J., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer. a prospective, population-based study in Sweden. JAMA 277 (1997) 467-471
8. Hanks G., Pajak T., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 22 (2004) 3972-3978
9. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). a phase III randomised trial. Lancet 360 (2002) 103-106
10. Kattan M., Stapleton A., Wheeler T., et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79 (1997) 528-537
11. Clark P., Peereboom D., Dreicer R., et al. Phase II trial of neoadjuvant estramustine phosphate and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57 (2001) 281-285
12. Dreicer R., Magi-Galluzzi C., Zhou M., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 (2004) 1138-1142
13. Hussain M., Smith D., El-Rayes B., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61 (2003) 774-780